Key result
Anthracycline chemotherapy shows no increase in arterial inflammation on FDG PET/CT in Hodgkin lymphoma.
Why the study?
The effect of anthracycline-based chemotherapy on systemic arterial inflammation in patients with Hodgkin lymphoma was unclear.
Does anthracycline-based chemotherapy increase arterial inflammation measured by FDG PET/CT in patients with Hodgkin lymphoma?
Comparison
Arterial FDG uptake before vs after chemotherapy
Design
Cohort study with PET/CT imaging
Follow-up
Mean 65 weeks
Authors
Loading...
No rise in arterial FDG uptake post-anthracycline in HL; leaves open PET/CT utility for vascular monitoring and requires prospective validation.
Cohort (n=52)
Does anthracycline-based chemotherapy increase arterial inflammation measured by FDG PET/CT in patients with Hodgkin lymphoma?
Anthracycline-based chemotherapy for Hodgkin lymphoma did not significantly increase arterial inflammation as measured by FDG PET/CT at an average follow-up of 65 weeks.
Lawal et al. (2020) conducted a cohort in Hodgkin lymphoma (n=52). Anthracycline-based chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Arterial FDG uptake (SUVmax and TBR) in multiple vascular beds. Anthracycline-based chemotherapy did not significantly increase arterial inflammation measured by FDG PET/CT in patients with Hodgkin lymphoma at an average follow-up of 65 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: